The Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) | Strategic Alliance Partners

April 01, 2024

The incorporation of immune checkpoint inhibitors has altered the treatment paradigm for endometrial cancer.

November 27, 2023

Subgroup analyses from non–small cell lung cancer clinical trials, such as the phase 3 POSEIDON and FLAURA2 trials, can help personalize treatment decisions with immunotherapy and targeted therapy based on individual mutational profiles.

October 25, 2023

Institutional Perspectives in Cancer: Lung Cancer - Chaired by Konstantinos Arnaoutakis, MD

September 08, 2023

Michael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.

September 07, 2023

Martin Cannon, PhD, discusses data seen with immune checkpoint inhibitors in patients with ovarian cancer and why these agents are not as effective in this population as they are in other cancer types.

September 01, 2023

Martin Cannon, PhD, delves into ongoing research on the use of dendritic cell vaccines to generate Th17 responses in patients with ovarian cancer and details how this could address a need for select patients with ovarian cancer.

August 31, 2023

Martin Cannon, PhD, details the history of investigating immune checkpoint inhibitors in patients with ovarian cancer and expands on the questions that need to be answered to potentially improve the activity of these agents in this patient population.

August 30, 2023

Heather R. Williams, MD, discusses the evolution of the ovarian cancer treatment paradigm over the past several decades, as well as the importance of continuing to investigate individualized treatment approaches in this population to expand therapeutic options after disease recurrence.

August 30, 2023

Martin Cannon, PhD, discusses explanations for the lack of success with immune checkpoint inhibitors in ovarian cancer, and how to potentially improve responses to immunotherapy approaches in this tumor type.

August 25, 2023

Heather R. Williams, MD, discusses the mechanism of action of antibody-drug conjugates and ADC targets under investigation in patients with ovarian cancer.

August 24, 2023

Heather R. Williams, MD, discusses ocular toxicities associated with antibody-drug conjugates and strategies for managing these toxicities in patients with ovarian cancer.

August 23, 2023

Martin Cannon, PhD, discusses the phase 1 investigation of the Th17 dendritic cell vaccine in ovarian cancer, and how it could potentially improve suboptimal responses when treated with immunotherapy alone in this population.

August 22, 2023

Michael J. Birrer, MD, PhD, discusses how the expansion of antibody-drug conjugates can address the need for more effective regimens in platinum-resistant ovarian cancer.

August 21, 2023

Carolina D. Schinke, MD, discusses the safety profile of talquetamab-tgvs in the phase 1/2 MonumenTAL-1 trial of patients with relapsed/refractory multiple myeloma.

August 16, 2023

Heather R. Williams, MD, discusses the importance of further exploring the use of antibody drug conjugates in ovarian cancer, specifically highlighting the investigation of mirvetuximab soravtansine in this population.

July 11, 2023

Michael J. Birrer, MD, PhD, highlights the effect of improved molecular characterization in endometrial cancer, the clinical significance of the KEYNOTE-775 trial, and recent changes in the frontline treatment landscape in advanced endometrial cancer.

June 30, 2023

Carolina D. Schinke, MD, discusses updated findings from the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

June 29, 2023

The treatment landscape for PNH is rapidly evolving, and clinicians have more effective and convenient treatment options for patients that have helped control the disease and improve survival. T

June 28, 2023

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

June 27, 2023

As part of the diagnostic work-up for a patient with newly diagnosed MCL, it is important to establish prognostic disease biology factors such as classical nodal morphology vs blastoid variant vs leukemic variant, TP53 mutation status, and Ki-67 reflective of proliferation.